Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the *NIS-LAMS** cohort

Background: The complex natural history of human papillomavirus (HPV) infections following a single HPV test can be modeled as competing-risks events (i.e., no-, transient- or persistent infection) in a longitudinal setting. The covariates associated with these compet ng events have not been previously assessed using competing-risks regression models. Objectives: To gain further insights in the outcomes of cervical HPV infections, we used univariate- and multivariate competing-risks regression models to assess the covariaies associated with these competing events. Study Design and Methods: Covariates associated with three competing outcomes (no-, transient- or persistent HR-HPV infection) were analysed in a sub-cohort of 1,865 women prospectively followed-up in the NIS (n = 3,187) and LAMS Study (n = 12,114). Results: In multivariate competing-risks models (with two other outcomes as competing events), permanently HR-HPV negative outcome was significantly predicted only by the clearance of ASCUS+Pap during FU, while three independent covariates predicted transient HR-HPV infections: i) number of recent (< 12 months) sexual partners (risk increased), ii) previous Pap screening history (protective), and history of previous CIN (increased risk). The two most powerful predictors of persistent HR-HPV infections were persistent ASCUS+Pap (risk increased), and previous Pap screening history (protective). In pair-wise comparisons, number of recent sexual partners and previous CIN history increase the probability of transient HR-HPV infection against the HR-HPV negative competing event, while previous Pap screening history is protective. Persistent ASCUS+Pap during FU and no previous Pap screening history are significantly associated with the persistent HR-HPV outcome (compared both with i) always negative, and ii) transient events), whereas multiparity is protective. Conclusions: Different covariates are associated with the three main outcomes of cervical HPV infections. The most significant covariates of each competing events are probably distinct enough to enable constructing of a risk-profile for each main outcome.

HPV; Natural history; Outcomes; Competing events; Competing-risks regression model; Transient infection; Persistent infection; Prospective follow-up; NIS Cohort; LAMS Study

[1] Östor A.G.: “Natural history of cervical intraepithelial neoplasia - a critical review”. Int. J. Gynecol. Pathol., 1993, 12, 186.

[2] Syrjänen K.J.: “Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated HPV”. Eur. J. Obstet. Gynecol. Reprod Biol 1996;65:45.

[3] Syrjänen K.J.: “Biological behaviour of cervical intraepithelial neoplasia”. In: Franco, E., Monsonego, J. (eds.). New Developments in Cervical Cancer Screening and Prevention. Blackwell Science, Oxford, 1997, 93.

[4] Syrjänen K.J.: “Natural history of HPV infections: Recent developments”. In: Monsonego J. (Ed.). 5th International Multidisciplinary Congress EUROGIN 2003. Monduzi Editore, Milano 2003, 1.

[5] Syrjänen K.: “Natural history of cervical HPV infections and CIN”. In: Syrjänen, K. and Syrjänen, S. Papillomavirus Infections in Human Pathology. J. Wiley & Sons, New York, 2000, 142.

[6] Syrjänen K., Väyrynen M., Saarikoski S., Mäntyjärvi R., Parkkinen S., Hippeläinen M., Castren O.: “Natural history of cervical Human papillomavirus (HPV) infections based on prospective follow-up”. Brit. J. Obstet. Gynaecol., 1985, 92, 1086.

[7] Syrjänen K., Mäntyjärvi R., Saarikoski S., Väyrynen M., Syrjänen S., Parkkinen S. et al.: “Factors associated with progression of cervical Human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up”. Brit. J. Obstet. Gynaecol., 1988, 95, 1096.

[8] Kataja V., Syrjänen K., Syrjänen S., Mäntyjärvi R., Yliskoski M., Saarikoski S. et al.: “Prospective follow-up of genital HPV infections: Survival analysis of the HPV typing data”. Eur. J. Epidemiol., 1990, 6, 9.

[9] Kataja V, Syrjänen S., Yliskoski M., Hippeläinen M., Väyrynen M., Saarikoski S. et al.: “Risk factors associated with cervical human papillomavirus (HPV) infections: A case-control study”. Am. J. Epidemiol., 1993, 138, 735.

[10] Syrjänen K., Kataja V., Yliskoski M., Chang F., Syrjänen S., Saarikoski S.: “Natural history of cervical Human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System”. Obstet. Gynecol., 1992, 79, 675.

[11] Wright T.C. Jr.: “Natural history of HPV infections”. J. Fam. Pract., 2009, 58, S3.

[12] Kulmala S.M., Shabalova I.P., Petrovitchev N., Syrjänen K.J., Gyllensten U.B., Syrjänen S.M.: “Prevalence of the most common high-risk HPV genotypes among women in the three new independents states of the former Soviet Union”. J. Med. Virol., 2007, 79, 771.

[13] Herrero R., Hildesheim A., Bratti C., Sherman M.E., Hutchinson M., Morales J. et al.: “Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica”. J. Natl. Cancer Inst., 2000, 92, 464.

[14] Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A.: “Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students”. Am. J. Epidemiol., 2003, 157, 218.

[15] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Acquisition of incident high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV Screening in the New Independent States (NIS) of the Former Soviet Union”. J. Clin. Microbiol., 2004, 42, 505.

[16] Louvanto K., Rintala M.A., Syrjänen K.J., Grénman S.E., Syrjänen S.M.: “Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study”. BMC Infect. Dis., 2011, 11, 179.

[17] Brummer O., Hollwitz B., Bohmer G., Kuhnle H., Petry K.U.: “Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia”. Gynecol. Oncol., 2006, 102, 517.

[18] Hildesheim A., Schiffman M.H., Gravitt P.E., Glass A.G., Greer C.E., Zhang T. et al.: “Persistence of type-specific human papillomavirus infection among cytologically normal women”. J. Infect. Dis., 1994, 169, 235.

[19] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Clearance of high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the Former Soviet Union”. Eur. J. Gynecol. Obstet. Reprod. Biol., 2005, 119, 219.

[20] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Age-specific incidence and clearance rates of high-risk Human Papillomavirus (HPV) infections in women subjected to HPV screening in the new independent states”. Int. J. STD & AIDS, 2005, 16, 217.

[21] Kjaer S.K., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E. et al.: “Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types?”. Cancer Epidemiol. Biomarkers Prev., 1997, 6, 799.

[22] Melkert P.W., Hopman E., van den Brule A.J., Risse E.K., van Diest P.J., Bleker O.P. et al.: “Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent”. Int. J. Cancer, 1993, 53, 919.

[23] Louvanto K., Syrjänen K.J., Grénman S.E., Rintala M.A., Syrjänen S.M.: “Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish Family HPV Study”. J. Clin. Microbiol., 2010, 48, 2665.

[24] Dalstein V., Riethmuller D., Pretet J.L., Le Bail C.K., Sautiere J.L., Carbillet J.P. et al.: “Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study”. Int. J. Cancer, 2003, 106, 396.

[25] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A., Podistov J.I. et al.: “Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the Former Soviet Union”. Eur. J. Gynaecol. Oncol., 2005, 26, 491.

[26] Schiffman M., Herrero R., DeSalle R., Hildesheim A., Wacholder S., Rodriguez A.C. et al.: “The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76.

[27] Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S.: “Human papillomavirus and cervical cancer”. Lancet, 2007, 370, 890.

[28] Wang S.S., Zuna R.E., Wentzensen N., Dunn S.T., Sherman M.E., Gold M.A. et al.: “Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants”. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 113.

[29] Belinson S., Smith J.S., Myers E., Olshan A., Belinson J., Pretorius R. et al.: “Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 2350.

[30] Syrjänen K.J.: “New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors”. Eur. J. Gynecol. Oncol., 2008, 29, 205.

[31] Syrjänen K.J.: “Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV16/18) prophylactic HPV vaccines”. Eur. J. Gynecol. Oncol., 2011, 32, 17.

[32] Louvanto K., Rintala M.A., Syrjänen K.J., Grénman S.E., Syrjänen S.M.: “Genotype-specific prevalence and persistence of genital high- and low-risk human papillomavirus (HPV) infections in women followed-up for 6 years in the Finnish Family HPV Study”. J. Infect. Dis., 2010, 202, 436.

[33] Xue X., Gange S.J., Zhong Y., Burk R.D., Minkoff H., Massad L.S. et al.: “Marginal and mixed-effects models in the analysis of human papillomavirus natural history data”. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 159.

[34] Fine J.P., Gray R.J.: “A proportional hazards model for the subdistribution of a competing risk”. J. Am. Stat. Assoc., 1999, 94, 496.

[35] Putter H., Fiocco M., Geskus R.B.: “Tutorial in biostatistics: Competing risks and multi-state models”. Stat. Med., 2007, 26, 2389.

[36] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Human Papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former SovietUnion”. J Lower Genital Tract Dis., 2002, 6, 97.

[37] Syrjänen K., Naud P., Derchain S.M., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: “Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study”. Anticancer Res., 2005, 25, 3469.

[38] Longatto-Filho A., Maeda M.Y.S., Eržen M., Branca M., Roteli-Martins C., Naud P. et al.: “Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening Study”. Acta Cytol., 2005, 49, 500.

[39] Sarian L., Derchain S.M., Naud P., Roteli-Martins C., Longatto-Filho A., Tatti S. et al.: “Evaluation of visual inspection with acetic acid (VIA), Lugol’s iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study”. J. Med. Screen, 2005, 12, 142.

[40] Longatto-Filho A., Eržen M., Branca M., Roteli-Martins C., Naud P., Derchain S. et al.: “Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS Study”. Int. J. Gynecol. Cancer, 2006, 16, 955.

[41] Syrjänen S., Shabalova I.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: “Sexual habits and Human papillomavirus (HPV) infections among women in three new independent states of the former Soviet Union”. Sex Transm. Dis., 2003, 30, 680.

[42] Syrjänen K., Shabalova I., Naud P., Sarian L., Derchain S., Kozachenko V. et al.: “Risk estimates for persistent High-Risk Human Papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease critically depend on reference category. Analysis of the combined prospective cohort of the NIS* and LAMS** studies”. Int. J. STD & AIDS, 2011, 22, 315.

[43] Kulmala S.M., Shabalova I., Petrovitchev N., Syrjänen K., Gyllenstein U., Johansson B., Syrjänen S.: “Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study”. Cancer Epidemiol. Biomarker Prev., 2007, 16, 17.

[44] Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S.: “Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis”. Am. J. Epidemiol., 2008, 168, 123.